BTK
信号通路图
研究领域
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S2680 | Ibrutinib (PCI-32765) | <1 mg/mL | 88 mg/mL | 45 mg/mL |
| S7173 | Spebrutinib (CC-292, AVL-292) | <1 mg/mL | 85 mg/mL | <1 mg/mL |
| S7257 | CNX-774 | <1 mg/mL | 100 mg/mL | 2 mg/mL |
| S7080 | RN486 | <1 mg/mL | 62 mg/mL | <1 mg/mL |
| S8679 | BTK inhibitor 1 (Compound 27) | <1 mg/mL | 95 mg/mL | <1 mg/mL |
| S8381 | BMS-986142 | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S8777 | Evobrutinib | <1 mg/mL | 86 mg/mL | 10 mg/mL |
| S8711 | ARQ 531 | <1 mg/mL | 95 mg/mL | 7 mg/mL |
| S8542 | Btk inhibitor 2 | <1 mg/mL | 86 mg/mL | 9 mg/mL |
| S8348 | BMS-935177 | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S7734 | LFM-A13 | <1 mg/mL | 72 mg/mL | <1 mg/mL |
| S7877 | ONO-4059 analogue | <1 mg/mL | 20 mg/mL | <1 mg/mL |
| S8294 | Olmutinib (HM61713, BI 1482694) | <1 mg/mL | 97 mg/mL | 23 mg/mL |
| S8116 | Acalabrutinib (ACP-196) | <1 mg/mL | 93 mg/mL | 93 mg/mL |
| S7051 | CGI1746 | <1 mg/mL | 100 mg/mL | 33 mg/mL |
| S8166 | tirabrutinib(GS-4059/ONO-4059) hydrochloride | <1 mg/mL | 98 mg/mL | 1 mg/mL |
- BTK抑制剂（16）
- 新BTK产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S2680 |
Ibrutinib (PCI-32765)Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。 |
Autoproliferation of B and CD4+ T cells upon addition of the selective BTK inhibitor ibrutinib or vehicle (DMSO) control (left graph). Right graph shows the HLA-DR expression (line) and survival (numbers) of B cells (mean ± SEM; n = 3 REM).
|
|
| S7173 |
Spebrutinib (CC-292, AVL-292)Spebrutinib (CC-292, AVL-292)是一个通过共价结合的，可以口服，并且具有高度选择性的BTK抑制剂，其IC50小于0.5 nM，展示了比其他被测激酶至少1400倍的选择性。Phase 1. |
Effects of AVL-292, CNX-774 and dasatinib on IgE-mediated histamine release in human basophils. Basophils (BA) obtained from three nonallergic donors (A). |
|
| S7257 |
CNX-774CNX-774是不可逆的，口服有效的高选择性BTK抑制剂，IC50<1 nM。 |
Effects of AVL-292, CNX-774 and dasatinib on IgE-mediated histamine release in human basophils. Basophils (BA) obtained from three nonallergic donors (A), three patients allergic to Der p 2, and three patients allergic to Phl p 5 (B and C) were preincubated in control medium (Co) or medium containing various concentrations of AVL-292, CNX-774, or dasatinib (0.001-1 μmol/L) at 37°C for 30 minutes. Then, cells were exposed to anti-IgE antibody E-124.2.8 (1 μg/mL; nonallergic donors) or recombinant allergens (1 μg/mL of rDer p 2 or rPhl p 5 in allergic patients) at 37°C for 30 minutes. After centrifugation, histamine concentrations were determined in cell-free supernatants and cell lysates. Histamine release is expressed as percentage of total histamine. Results show the percentage of control and represent mean SD from three independent experiments (three donors). Asterisk (*): P<0.05 by Student's t test with Bonferroni correction |
|
| S7080 |
RN486RN486是一种有效的选择性BTK 抑制剂，IC50为4 nM。 |
||
| S8679New |
BTK inhibitor 1 (Compound 27)BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM. |
||
| S8381New |
BMS-986142BMS-986142是一种有效、高选择性的、可逆的BTK小分子抑制剂，IC50为0.5 nM。在384种激酶试验中，BMS-986142对BTK的选择性相较于对TEC、ITK、BLK、TXK和BMX的选择性在100倍以内。 |
||
| S8777New |
EvobrutinibEvobrutinib是一种高度选择性的BTK抑制剂，IC50为37.9 nM，具有潜在的抗肿瘤活性。 |
||
| S8711New |
ARQ 531ARQ 531是一种ATP竞争性的酪氨酸激酶抑制剂，靶向BTK，IC50为0.85 nM。它具有明显的激酶选择性，对几种关键的致瘤因子（如TEC、Trk和Src中的一些家族成员）具有强抑制活性。 |
||
| S8542New |
Btk inhibitor 2Btk inhibitor 2是BTK抑制剂。 |
||
| S8348New |
BMS-935177BMS-935177是一种有效的、可逆的BTK抑制剂，IC50为2.8 nM，具有良好的激酶选择性。它对BTK比对其他激酶如TEC, BMX, ITK, and TXK更有效力，选择性是其5-67倍。 |
||
| S7734 |
LFM-A13LFM-A13是一种特异性布鲁顿氏酪氨酸激酶(BTK)抑制剂，IC50为2.5 μM,选择性比其他蛋白激酶，包括JAK1，JAK2，HCK，EGFR，和 IRK高100多倍。 |
Cell-free kinase assay of IFN-gR2 phosphorylation at Y289 by constitutively active BTK with or without BTK inhibitor LFM-A13 (100 mM). WCL, whole-cell lysate; DIC, differential interference contrast microscopy.
|
|
| S7877 |
ONO-4059 analogueONO-4059 analogue 是一种ONO-4059类似物，其是一种高度有效的选择性口服BTK抑制剂，IC50为23.9 nM。Phase 1。 |
||
| S8294 |
Olmutinib (HM61713, BI 1482694)Olmutinib是一种新型的EGFR突变特效性酪氨酸激酶抑制剂、布鲁顿氏酪氨酸激酶抑制剂。 |
||
| S8116 |
Acalabrutinib (ACP-196)Acalabrutinib(ACP-196)是选择性的第二代BTK抑制剂，抑制B细胞表面原抗体信号通路的激活，IC50为3 nM。它具有很好的靶标特异性，对BTK的选择性比对其他TEC激酶家族成员如ITK、TXK、BMK和TEC的选择性高323-, 94-, 19-, 9-倍。对EGFR没有活性。 |
Comparison of the impairment of ADCC against primary CLL cells by different irreversible BTK inhibitors. The antibody-dependent increase in the percentages of minimal calcein retention was determined with 3-fold excess of 1708-LC3E11 effector cells over CLL target cells in seven independent experiments. (a) Asterisks above the boxes and whiskers denote the significance of enhanced cytotoxicity compared to the control without addition of antibodies and inhibitors as determined by paired t-tests. Furthermore combination treatment was compared to that with anti-CD20 antibodies as single agents. (b) The mean differences ± SEM in the cytotoxicity against CLL cells in the presence and absence of rituximab and obinutuzumab were calculated from the data shown in (a). The ADCC of rituximab and obinutuzumab was compared by paired two-tailed t-test. *p<0.05; **p<0.01; ***p<0.001.
|
|
| S7051 |
CGI1746CGI1746 是强效的高度选择性的小分子Btk抑制剂，其IC50为1.9 nM。 |
IL-1β cleavage (A, B) in platelets activated by collagen or thrombin is reduced in the presence of the BTK inhibitor CGI1746.
|
|
| S8166 |
tirabrutinib(GS-4059/ONO-4059) hydrochlorideONO-4059 (GS-4059)是一种高度有效的、选择性的BTK抑制剂，IC50为2.2 nM。 |
